Efficacy and Safety of Temozolomide Given Every Other Week as a Second-Line Treatment for Advanced Neuroendocrine Carcinomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
ESMO Open 2024 Apr 13;9(5)103003, C von Arx, G Della Vittoria Scarpati, L Cannella, O Clemente, AL Marretta, A Bracigliano, F Picozzi, D Iervolino, V Granata, R Modica, A Bianco, C Mocerino, A Di Mauro, A Pizzolorusso, A Di Sarno, A Ottaiano, S TafutoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.